New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
06:22 EDTHZNP, ESRX, CVSHorizon Pharma said Duexis, Vimovo to be placed on CVS, Express exlclusion lists
Horizon Pharma (HZNP) said it has been verbally notified that in August, two pharmacy benefit managers, CVS Caremark (CVS) and Express Scripts (ESRX), expect to announce DUEXIS and VIMOVO will no longer be on their formularies and will be placed on their exclusion lists effective January 1, 2015. As a change in Caremark and ESI formulary status would not take effect until 2015, Horizon Pharma does not expect this potential action to impact the financial guidance of $270M-280M for net revenues and $80M-90M for adjusted EBITDA for fiscal 2014 as provided in first quarter earnings press release dated May 9. In response to potentially being placed on Caremark’s and ESI’s exclusion lists, the company said it will immediately accelerate patient and physician focused commercial model to focus prescriptions through other channels such as our Prescriptions Made Easy program, continue working with many of the other PBMs and evaluate price increases. We estimate approximately 20%-30% of DUEXIS and VIMOVO prescriptions could be impacted by the potential actions by Caremark and ESI. In the future, if additional healthcare plans adopt the Caremark or ESI exclusion lists or otherwise exclude DUEXIS or VIMOVO from the formularies they use, which they are not required to do, there could possibly be additional DUEXIS and VIMOVO prescriptions affected.
News For HZNP;CVS;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 21, 2015
07:48 EDTCVSCVS Health to hold a conference call
Conference call to discuss definitive agreement to acquire Omnicare will be held on May 21 at 8:30 am. Webcast Link
07:21 EDTCVSOmnicare elevated into CVS Health acquiring for $98 per share
Subscribe for More Information
07:06 EDTCVSCVS Health agree to acquire Omnicare for $98 per share
Subscribe for More Information
07:04 EDTCVSCVS Health agree to acquire Omnicare for $98 per share
Subscribe for More Information
May 20, 2015
18:19 EDTCVSOmnicare up about 5% from close after talks of being acquired by CVS Health
Subscribe for More Information
18:10 EDTCVSCVS Health in late stage talks to acquire Omnicare, Bloomberg says
CVS Health (CVS) is in advanced talks to buy Omnicare (OCR), Bloomberg reports, citing people with knowledge of the matter. A deal could be reached as soon as this week, the sources added. Reference Link
18:00 EDTCVSCVS Health reportedly in advanced talks to acquire Omnicare, Bloomberg says
Subscribe for More Information
11:51 EDTESRXExpress Scripts' Medco to pay $7.9M to resolve kickback allegations
Medco Health Solutions, a wholly-owned subsidiary of the pharmacy benefit manager Express Scripts Holding Company (ESRX), of Missouri, has agreed to pay the government $7.9M to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act, the Justice Department announced. Medco provides pharmacy benefit management services to clients who receive subsidies under the Medicare Retiree Drug Subsidy program. The settlement resolves allegations that Medco solicited remuneration from AstraZeneca, a pharmaceutical manufacturer, in exchange for identifying Nexium as the “sole and exclusive” proton pump inhibitor on certain of Medco’s prescription drug lists known as formularies. The United States alleged that Medco received some or all of the remuneration from AstraZeneca in the form of reduced prices on the following AstraZeneca drugs: Prilosec, Toprol XL and Plendil. The United States contended that this kickback arrangement between Medco and AstraZeneca (AZN) violated the Federal Anti-Kickback statute, and thereby caused the submission of false or fraudulent claims for Nexium to the Retiree Drug Subsidy Program. In January 2015, the United States and AstraZeneca reached a $7.9M settlement to resolve kickback allegations arising out of the same conduct. This civil settlement resolves a lawsuit filed under the qui tam, or whistleblower, provision of the False Claims Act, which allows private citizens with knowledge of false claims to bring civil actions on behalf of the government and to share in any recovery. The lawsuit was filed by former AstraZeneca employees Paul DiMattia and F. Folger Tuggle, whose share of the settlement has not been determined. The settlement with Medco was the result of a coordinated effort among the Civil Division, the U.S. Attorney’s Office of the District of Delaware and HHS-OIG.
10:00 EDTESRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:21 EDTCVSUBS to hold a conference
Subscribe for More Information
May 19, 2015
16:41 EDTESRXExpress Scripts initiated with a Neutral at Baird
Target $94.
07:26 EDTHZNPHorizon Pharma meeting takeaways support investment thesis, says UBS
Subscribe for More Information
07:17 EDTCVSCVS Health has a conference call hosted by JPMorgan
JPMorgan Analyst Gill will host a conference call with CEO Larry Merlo on May 21 at 11 am.
May 15, 2015
10:01 EDTHZNPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:05 EDTHZNPHorizon Pharma initiated with a Buy at Jefferies
Target $37.
May 14, 2015
11:08 EDTESRXExpress Scripts management to meet with Maxim
Meeting to be held in St. Louis, MO on May 21 hosted by Maxim.
10:56 EDTHZNPOptions with decreasing implied volatility
Subscribe for More Information
May 13, 2015
11:47 EDTCVSCVS Health says to pay $22M in settlement with DEA, USAO
CVS Health said in a regulatory filing that it has entered into an agreement with the U.S. Attorney’s Office for the Middle District of Florida and the U.S. Drug Enforcement Administration to resolve previously-disclosed allegations relating to the dispensing of certain controlled substances in Florida. CVS Health agreed to pay $22M and the settlement resolves all civil matters between the Company and the DEA in the state of Florida. This payment amount has been fully accrued for in prior fiscal periods.
11:08 EDTHZNPOptions with decreasing implied volatility
Subscribe for More Information
06:47 EDTHZNPHorizon Pharma UCD treatment has upside potential, says Piper Jaffray
After surveying 16 physicians who treat patients with urea cycle disorders, Piper Jaffray sees "ample room" for further growth of Horizon Pharma's Ravicti. Piper believes its Ravicti estimates could prove conservative and reiterates an Overweight rating on Horizon with a $38 price target.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use